Author/Authors :
Goudarzi, Mehdi Department of Microbiology - School of Medicine - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Heidary, Mohsen Department of Medical Microbiology - Faculty of Medicine - Iran University of Medical Sciences, Tehran, Iran , Azad, Mehdi Department of Medical Laboratory Sciences - School of Paramedicine - Qazvin University of Medical Sciences, Iran , Fazeli, Maryam Collaborating Center for Reference and Research on Rabies - Pasteur Institute of Iran, Tehran, Iran , Goudarzi, Hossein Department of Microbiology - School of Medicine - Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract :
Aim: The purpose of this study was to determine the antibiotic susceptibility pattern and distribution of integron in H. pylori isolates
collected from patients referred to private health care centers in Tehran, Iran.
Background: Antibiotic resistance is the main reason for failure of Helicobacter pylori therapy. Integrons as genetic reservoirs play
main roles in the dissemination of antimicrobial resistance gene.
Methods: During a 12-month cross-sectional study period, 65 H. pylori isolates were recovered from 124 biopsy specimens. Isolates
were subjected to susceptibility testing using by Epsilometer test according to the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) guideline. PCR was used to detect different types of integrons.
Results: Antimicrobial susceptibility testing revealed that 73.8% of isolates were resistant to metronidazole, 43.1% to clarithromycin,
29.2% to tetracycline, 27.7% to amoxicillin, 23.1% to rifampicin and 13.4% to levofloxacin. Frequency of multidrug resistance among
H. pylori isolates was 26.1%. The most predominant resistance profiles among our isolates were included resistance to clarithromycin
and metronidazole (20%). Class 1 and 2 integrons were detected in 8 (12.3%) and 15 (23.1%) of the isolates, respectively.
Conclusions: The high prevalence of multidrug resistance and frequency of class 2 integron in this survey can be a warning for
clinicians. Continuous surveillance is necessary for the development of new treatment protocols to prevent the treatment failures and
also further spread of resistant isolates.